Etcamah / Camizestrant for Locally Advanced or Metastatic ER-Positive/HER2-Negative Breast Cancer

As of August 2026, MARA’s assessment finds Etcamah / Camizestrant’s reimbursement risk concentrated in care pathway integration and quality of life, with clinical effectiveness a strength; the current MARA Rating and full rationale are available in the report.

The assessment also weighs safety and adverse effects: what harms arrive alongside the benefit, which payers set against the gains before funding a treatment. The strength recorded in clinical effectiveness carries weight because that domain asks how much additional benefit the drug demonstrated over the care patients already receive — the first question every payer asks.

Oncology

This rating sits within MARA’s Oncology coverage, alongside 153 other independently assessed treatments in the same area.

What payers will ask

Is the clinical benefit the kind payers reward? — Clinical effectiveness

The SERENA-6 trial provides robust evidence of camizestrant’s efficacy in delaying first progression with a HR of 0.44 (95% CI 0.31–0.60; p<0.00001) compared to continued AI. However, overall survival benefit is not established, and the trial does not address the broader treatment strategy question.

Does the economic case hold at the expected price? — Cost effectiveness

No public ICER or cost-utility analysis is available, and no economic model has been completed for camizestrant.

Is there quality-of-life evidence payers weigh? — Quality of life

While PROs favored camizestrant in global health/QoL and pain, FDA noted significant limitations in data collection and reliability, reducing confidence in these results.

Does the safety profile hold up for payers? — Safety and Adverse Effects

Camizestrant has a moderate-to-high confidence in common short-term safety, with visual effects and bradycardia as notable AEs. Long-term safety data is less mature, particularly for ribociclib combinations.

Was the drug compared against what payers expect? — Comparator Selection

The comparator (AI + CDK4/6 inhibitor) is relevant to the standard of care, but the trial does not compare against a strategy of waiting for progression before switching to an ESR1-targeted therapy.

Is the population defined the way payers need it? — Patient Population and Subgroups

The trial population is well-defined and representative of the target population, but generalizability outside this specific group is limited.

Does the drug fit how care is delivered and paid for? — Care Pathway Integration

The treatment requires a significant change in care pathway with serial molecular surveillance, which is not yet characterized in routine practice.

Are the wider system costs understood? — Resource Use and Cost Implications

No budget-impact or resource information is presented, and no monetary values for resource categories are available.

Would the evidence survive payer scrutiny? — Evidence Quality and Robustness

The evidence is strong for PFS with a high-quality phase III trial, but weaker for OS, HRQoL, and economic outcomes.

How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts

There is high uncertainty regarding OS and economic outcomes, and the broader system impacts are not quantified.

This rating replaces the earlier June 2026 rating of the same drug and indication — still on the record here.

Request the current rating

Be alerted when this rating changes:

Related Reimbursement Risk Assessments

Public record

The entries below are official decisions and assessments concerning this drug and indication, listed with their dates as a matter of record. The assessment on this page reflects the evidence available as of its date.

22 May 2026 — European Union (CHMP), regulatory opinion: positive opinion for ESR1-mutated disease in combination with a CDK4/6 inhibitor; European Commission decision pending. official record

Full Legal Disclaimer and Usage Terms

The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer here.